On April 1, 2019, Alpha Cell Biotechnology UK hosts a seminar of "Opening a new era of cell therapy" in the Haimei Shanghai HQ. Alpha Cell’s current key project is led by it’s co-founder Dr. Chen Rongjun, an establish bio-med professor from Imperial College London. The project is   seeded by Haimei Investment Holdings. On the day of the event, 20 top domestic capital parties came to participate in the event.

Dr. Chen Rongjun, co-founder and patent holder of AlphaCell Biotech, introduced the advantages and future of AlphaCells Biotech project. "We're not making drugs, we're not targeting any particular disease," Dr. Chen said. Our patent is the solution to two of the major problems in immunotherapy today. The first is cell preservation. Cells are taken out of the body and transformed. The window is 18 hours. Currently, the only storage in the world is using DMSO. The second is cell modification. Our first product is to put the required materials into the cell within 15 minutes, so as to achieve the purpose of cell modification. AlphaCells Cell Technology is one of the world's leading technologies for cell preservation and cell therapy, and will redefine the immune cell therapy and stem cell therapy markets in the future.

If the 20th century was the age of medicine, the 21st is the age of cell therapy. Cell therapy has been making new breakthroughs in recent years, providing choices for intractable diseases and driving profound changes in the biotechnology industry, which is expected to help China become a leader in the biotechnology industry. In the future, Dr Chen will continue his research and develop a industrialization base in China which focus on clinical trials and equipment production.